The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2024 Status: In Process
This bill aims to regulate pharmacy benefits managers (PBMs), pharmacies, and prescription drug benefits. It requires that any payments a covered person makes for a prescription drug must be applicable to any deductibles in the …
SF 554 – Iowa
Introduced: 2024 Status: In Process
This bill is designed to regulate the operations of Pharmacy Benefits Managers (PBMs) in the state of Iowa. It introduces a system of reverse auctions to determine which PBM will provide services for public sector …
LB 984 – Nebraska
Introduced: 2024 Status:
This bill aims to regulate the actions relating to the distribution of drugs by 340B entities. A 340B entity refers to an entity authorized to participate in the federal 340B drug discount program which allows …
LB 990 – Nebraska
Introduced: 2024 Status:
A BILL FOR AN ACT relating to the Pharmacy Benefit Manager Licensure and Regulation Act; to amend sections 44-4603, 44-4604, 44-4606, and 44-4610, Revised Statutes Cumulative Supplement, 2022; to define and redefine terms; to change …
HB 490 – Kentucky
Introduced: 2024 Status: In Process
Create a new section of KRS Chapter 315 to define terms, prohibit discrimination against 340B covered entities by pharmaceutical manufacturers, and authorize the Attorney General to investigation violations.
HB 823 – Kentucky
Introduced: 2024 Status: In Process
Create new sections of KRS Chapter 194A to establish the Kentucky Prescription Drug Affordability Board; establish the duties and membership of the board; provide that the board be a budgetary unit of the Office of …
SB 1164 – Arizona
Introduced: 2024 Status: In Process
This bill amends title 20, chapter 25, article 2 of the Arizona Revised Statutes, establishing regulations for Pharmacy Benefit Managers (PBMs). PBMs are third-party administrators of prescription drug programs. The bill prohibits PBMs from limiting …
Next | See all Legislation Records
District Court: Eastern District of Pennsylvania Status: Decided
FTC alleged AbbVie sued generic companies for patent infringement over their proposed generic version of the testosterone gel, AndroGel, without justifiable grounds but merely to …
In the Matter of Impax Laboratories Inc. – Federal
District Court: Federal Trade Commission Status: Pending
The Federal Trade Commission sued generic drugmaker Impax Laboratories Inc. for allegedly accepting more than $100 million to delay its release of a generic version …
In re: EPIPEN (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigtion – Illinois, Kansas, New Jersey, Washington
District Court: District of Kansas Status: Pending
The plaintiffs in the case allege Mylan N.V. created and exploited an EpiPen monopoly by providing aggressive rebates and incentives to pharmacy benefit managers to …
Sentry Data Sys. v. CVS Health – Florida
District Court: S.D. Florida Status: Pending
340B administrator Sentry Data Systems sued CVS pharmacy alleging that since CVS aquired Wellpartner, the company has engaged in unlawful tying, using its status as …
Previous | See all Litigation Records
News & Opinions
![](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2015/04/Law360.jpg)
![Modern Healthcare](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2014/05/modern-healthcare.jpg)
![Modern Healthcare](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2014/05/modern-healthcare.jpg)
![The Wall Street Journal](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2018/06/wall-street-journal-logo.jpg)
Articles & Reports
Health Affairs Forefront November 28, 2023
Health Affairs Forefront November 16, 2023
Health Affairs November 6, 2023
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered